Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:45:35.581Z.
Calculation as of: 2026-10-06T22:45:35.581Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$747.61M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$753.02M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$761.37M
EV/EBITDA Ratio
18.31x
TTM Avg
16.06x
3Y Avg
17.33x
5Y Avg
27.55x
Market Cap
$723.18M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$721.69M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$714.37M
EV/EBITDA Ratio
N/A
TTM Avg
867.40x
3Y Avg
862.35x
5Y Avg
862.35x
Market Cap
$709.65M
EV/EBITDA Ratio
2.84x
TTM Avg
4.78x
3Y Avg
5.46x
5Y Avg
7.57x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $742.70M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $747.61M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.02M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.37M | 18.31x | 16.06x | 17.33x | 27.55x |
| Candel Therapeutics, Inc. (CADL)vs › | $723.18M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | N/A | N/A | N/A | N/A |
| Sana Biotechnology, Inc. (SANA)vs › | $765.30M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $714.37M | N/A | 867.40x | 862.35x | 862.35x |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 2.84x | 4.78x | 5.46x | 7.57x |
| Geron Corporation (GERN)vs › | $776.24M | N/A | 800.36x | 800.36x | 800.36x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
